Scientists Cautiously Suggest GLP-1s Are Safe to Use Around Pregnancy

Why It Matters

The study informs obstetricians and endocrinologists about the relative safety of GLP‑1 drugs in early pregnancy, potentially shaping prescribing guidelines and patient counseling as demand for these agents grows.

Key Takeaways

• Study reviews 49,000+ pregnancies exposed to GLP‑1 agonists.
• No significant rise in major birth defects found.
• Slight increase in renal malformations noted, likely due to maternal disease.
• Findings caution against routine GLP‑1 use in pregnancy but reassure inadvertent exposure.

Pulse Analysis

Weight‑loss medications that target the glucagon‑like peptide‑1 receptor have surged in popularity, driven by their potent appetite‑suppressing effects and impressive glycaemic control. Ozempic, Wegovy and the newer Mounjaro are now common prescriptions for obesity and type 2 diabetes, and many women of child‑bearing age are using them to meet BMI criteria for assisted‑reproductive technologies. Historically, pre‑clinical data raised red flags about teratogenicity, prompting clinicians to advise discontinuation before conception despite the drugs’ growing ubiquity.

The University of St Andrews team compiled data from ten cohort and observational studies, covering more than 49,000 pregnancies with periconceptional GLP‑1 exposure spanning 20 years. Their meta‑analysis found no statistically significant increase in major congenital anomalies, preterm birth, or adverse obstetric outcomes. A modest uptick in renal malformations reached statistical significance, but the authors argue this likely reflects confounding by maternal obesity or diabetes—conditions independently linked to fetal kidney defects—rather than a direct drug effect. The rigorous systematic approach and large sample size lend weight to the conclusion that inadvertent exposure is unlikely to cause severe fetal harm.

Clinically, the findings offer a measured reassurance for patients who discover a pregnancy while on GLP‑1 therapy, allowing providers to shift focus from abrupt drug cessation to comprehensive prenatal care. Nevertheless, the authors caution against routine use of these agents during pregnancy, underscoring the need for prospective trials with long‑term follow‑up. As insurers and pharmaceutical firms anticipate broader indications for GLP‑1 drugs, the study may influence guideline committees to refine recommendations, balancing the drugs’ metabolic benefits against the still‑uncertain long‑term fetal safety profile.